Heart Failure Clinical Trial
Official title:
Tailor-CRT: Better Application of Cardiac Resynchronization Therapy by Automated and Improved Selection of Location and Timing of Stimulation
Approximately one third of patients treated with cardiac resynchronization therapy (CRT) do not derive any clinical benefit. CRT response can be improved by tailoring LV lead placement and programming of atrio-ventricular (AV) and inter-ventricular (VV) stimulation intervals to the individual patient. However, the best strategy to optimize lead positioning and device programming still remains to be established. Earlier work in our research group suggests that the vector cardiogram (VCG) can be used to determine the optimal LV lead position and AV- and VV-intervals, and pilot studies showed the feasibility to derive a VCG-like signal (D-VCG) from the implanted pacing electrodes. Other studies have suggested that the best position for the LV electrode is the region of latest electrical activation. The region of latest electrical activation can be identified by measuring the electrical delay on the LV lead (LVLED) during implantation. The objective of this study is to investigate whether D-VCG can be used to determine the optimal AV- and VV-interval and whether VCG and LVLED can be used to determine the optimal LV lead position.
Cardiac resynchronization therapy (CRT) is an established treatment for heart failure (HF)
patients with severe left ventricular (LV) systolic impairment and delayed electrical
impulse conduction through the ventricles, such as left bundle-branch block (LBBB). Since
initial approval of the therapy over 10 years ago, there have been hundreds of thousands of
implants worldwide. In The Netherlands, currently more than 2000 CRT devices are implanted
each year. In a heart with LBBB, electrical activation of the lateral LV free wall is
delayed, which leads to dyssynchronous and inefficient LV mechanical contraction and
compromised LV pump function. The positive impact of CRT on LV pump function is attributed
to paced pre-excitation of the delayed activated lateral LV wall. CRT is most commonly
applied by pacing the right ventricle (RV) and LV lateral wall (almost) simultaneously. This
corrects the abnormal LV electrical activation and resynchronizes LV mechanical contraction,
which in turn results in improved LV pump function.
Despite the striking effectiveness of CRT, 30-50% of apparently suitable patients show
little or no improvement. Previous studies have shown that the response to CRT can be
improved by tailoring LV lead placement and programming of atrioventricular (AV) and
inter-ventricular (VV) stimulation intervals to the individual patient. In clinical
practice, echocardiographic techniques are the most widely employed for CRT optimization.
However these techniques are subject to large measurement errors and inter- and
intra-observer variability. A more accurate technique is invasive assessment of acute
hemodynamic response to CRT, with the most widely used invasive hemodynamic parameter being
the maximum rate of LV systolic pressure rise (LVdP/dtmax). However, the invasive and
time-consuming nature of this approach limits its use in clinical practice. Thus, the best
strategy to optimize lead positioning and device programming still remains to be
established.
Earlier work in our research group suggests that the vectorcardiogram (VCG) can be used to
determine the optimal LV lead position and AV- and VV-intervals, and pilot studies showed
the feasibility to derive a VCG-like signal (D-VCG) from the implanted pacing electrodes.
Other studies have suggested that the best position for the LV electrode is the region of
latest electrical activation. The region of latest electrical activation can be identified
by measuring the electrical delay on the LV lead (LVLED) during implantation. Validation of
these techniques for tailoring LV lead positioning and AV- and VV- stimulation intervals to
the individual patient, will provide non-invasive and easy methods to optimize CRT
application and improve response rate.
The objective of this study is to investigate whether D-VCG can be used to determine the
optimal AV- and VV-interval and whether VCG and LVLED can be used to determine the optimal
LV lead position. Validation of these techniques for tailoring LV lead positioning and AV-
and VV- stimulation intervals to the individual patient, will provide non-invasive and easy
methods to optimize CRT application and improve response rate.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Active, not recruiting |
NCT05896904 -
Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction
|
N/A | |
Completed |
NCT05077293 -
Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
|
||
Recruiting |
NCT05631275 -
The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
|
||
Enrolling by invitation |
NCT05564572 -
Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology
|
N/A | |
Enrolling by invitation |
NCT05009706 -
Self-care in Older Frail Persons With Heart Failure Intervention
|
N/A | |
Recruiting |
NCT04177199 -
What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
|
||
Terminated |
NCT03615469 -
Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY)
|
N/A | |
Recruiting |
NCT06340048 -
Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure
|
Phase 1/Phase 2 | |
Recruiting |
NCT05679713 -
Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
|
||
Completed |
NCT04254328 -
The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure
|
N/A | |
Completed |
NCT03549169 -
Decision Making for the Management the Symptoms in Adults of Heart Failure
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05538611 -
Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
|
||
Recruiting |
NCT04262830 -
Cancer Therapy Effects on the Heart
|
||
Completed |
NCT06026683 -
Conduction System Stimulation to Avoid Left Ventricle Dysfunction
|
N/A | |
Withdrawn |
NCT03091998 -
Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support
|
Phase 1 | |
Recruiting |
NCT05564689 -
Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy
|